STOCK TITAN

Adaptive Biotechnologies Corporation (ADPT) Stock News, Apr-Aug 2023

ADPT NASDAQ

Adaptive Biotechnologies Corporation reports company developments tied to immune-driven diagnostics and immune medicine. The commercial-stage biotechnology company applies a proprietary platform to translate adaptive immune system genetics into clinical products, with operating activity organized around Minimal Residual Disease (MRD) and Immune Medicine.

Recurring updates for ADPT include clonoSEQ MRD testing adoption, MRD revenue trends, pharma regulatory milestone revenue, operating expense guidance, and quarterly financial results. Company news also covers immune receptor and TCR-antigen data partnerships, autoimmune and cancer-related research applications, investor conference participation, and management commentary on the company’s diagnostic and drug-development collaborations.

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.44%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.12%
Tags
conferences earnings
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.30%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.86%
Tags
conferences
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.27%
Tags
-
Rhea-AI Summary

Adaptive Biotechnologies Corporation (Nasdaq: ADPT) announced its participation in the BofA Securities Healthcare Conference in Las Vegas on May 9, 2023, at 5:00 p.m. Pacific Time. The company will engage in a fireside chat, which interested parties can access via a live and archived webcast on their website.

Adaptive Biotechnologies focuses on translating the genetics of the adaptive immune system into clinical products for diagnosing and treating diseases such as cancer, autoimmune disorders, and infectious diseases. With a proprietary immune medicine platform, the company aims to develop customized clinical products tailored to individual patients, enhancing the efficiency of disease diagnosis and treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.55%
Tags
conferences
-
Rhea-AI Summary

Adaptive Biotechnologies (Nasdaq: ADPT) has announced a strategic collaboration with Takeda to utilize its clonoSEQ® Assay for assessing minimal residual disease (MRD) in patients with hematologic malignancies. The partnership aims to enhance the development and commercialization of Takeda's investigational therapies. This multi-year agreement will incorporate existing and future programs, with Adaptive receiving upfront and potential milestone payments. The clonoSEQ Assay is the only FDA-cleared test specifically for MRD in certain blood cancers, offering high accuracy and sensitivity. Both companies emphasize the importance of MRD assessment in predicting patient outcomes and guiding treatment plans.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.18%
Tags
none
Rhea-AI Summary

Adaptive Biotechnologies (Nasdaq: ADPT) announced it will report its financial results for the first quarter of 2023 on May 3, 2023, after market close. A conference call will take place at 1:30 p.m. PT / 4:30 p.m. ET, which will be accessible via the company’s website. The company focuses on translating the genetics of the adaptive immune system into clinical products for diagnosing and treating diseases, including cancer and autoimmune disorders. Their proprietary platform aims to unlock the full potential of the immune system, enhancing diagnosis and treatment precision. The company emphasizes its commitment to developing individualized immune-driven clinical products.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.23%
Tags
conferences earnings

FAQ

What is the current stock price of Adaptive Biotechnologies (ADPT)?

Adaptive Biotechnologies (ADPT) last closed at $28.49.

What is the market cap of Adaptive Biotechnologies (ADPT)?

The market cap of Adaptive Biotechnologies (ADPT) is approximately $4.6B.